U.S. MARKETS FOR DIAGNOSTIC ONCOLOGY PRODUCTS

447 Pages | 97 Exhibits | 2007 Analysis | Forecasts Through 2010 Product Family: Market Reports




OVERVIEW:
It is estimated that 1.4 million people in the U.S. will be diagnosed with cancer in 2007--this does not include basal or squamous cell skin cancers, which will account for another million new cancer cases. In the fight against cancer, which is the second-leading cause of death in the U.S. after heart disease (one in four people will die from cancer this year), remarkable advancements have been made in developing sophisticated tools to detect malignancies at their earliest and most treatable stages.

More than 197.8 million diagnostic oncology procedures were performed in the U.S. in 2006, in which various diagnostic imaging platforms, in vitro diagnostic testing techniques, tissue biopsy, and other cancer screening methods were utilized; these procedures generated approximately $4.2 billion in corresponding product sales. Growing at a compound annual rate of 5.0%, combined sales of diagnostic oncology products are projected to reach an estimated $5.2 billion in the year 2010.

This dynamic, new report from Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the U.S. diagnostic oncology products market.

Covered topics in this report include automated and vacuum-assisted less-invasive breast biopsy systems; automated Papanicolaou smear preparation/screening systems; biomolecular technologies for cancer detection and profiling; computer-aided detection systems; computed tomography systems; conventional X-ray-based imaging systems; core biopsy needles and delivery systems; developments in site-specific cancer markers; diagnostic ultrasound systems; fecal occult blood testing; genetic cancer markers; human papillomavirus testing; imaging contrast agents and radiopharmaceuticals; magnetic resonance imaging systems; mammography systems; native tissue fluorescence; near-infrared tomography; nuclear medicine/molecular imaging systems; risk factors associated with the development of cancer; statistics on new cancer cases, cancer prevalence, and deaths due to cancer; tumor-associated cancer markers

TABLE OF CONTENTS:

EXECUTIVE SUMMARY

i.             New Cancer Cases, Cancer Prevalence, and Deaths Due to Cancer

ii.             Diagnostic Oncology Procedures

iii.           Diagnostic Oncology Products

a.           Diagnostic Imaging Platforms

i.       Conventional X-Ray-Based Imaging Systems

ii.       Mammography Systems

iii.     Computed Tomography Systems

iv.     Magnetic Resonance Imaging Systems

v.     Nuclear Medicine/Molecular Imaging Systems

vi.     Diagnostic Ultrasound Systems

b.           Imaging Contrast Agents and Radiopharmaceuticals

i.       X-Ray Contrast Media

ii.       Magnetic Resonance Imaging Contrast Media

iii.     Nuclear Medicine/Molecular Imaging Radiopharmaceuticals

c.             Computer-Aided Detection Systems

d.           Less-Invasive Biopsy Products

i.       Automated and Vacuum-Assisted Breast Biopsy Devices

ii.       Core Biopsy Needles and Delivery Devices

e.           Automated Papanicolaou Smear Preparation/Screening Systems

f.             Cancer Marker Testing Systems

 

Exhibit ES-1:       Estimated New Cases, Prevalence, and Deaths for Selected Types of Cancer

Exhibit ES-2:       Diagnostic Oncology, Procedure Volumes Forecast, 2005-2010

Exhibit ES-3:       Diagnostic Oncology Products, Market Forecast, 2005-2010

Exhibit ES-4:       Diagnostic Imaging Systems, Market Forecast, 2005-2010

Exhibit ES-5:       Conventional X-Ray-Based Imaging Systems, Market Forecast, 2005-2010

Exhibit ES-6:       Mammography Systems, Market Forecast, 2005-2010

Exhibit ES-7:       Computed Tomography Systems, Market Forecast, 2005-2010

Exhibit ES-8:       Magnetic Resonance Imaging Systems, Market Forecast, 2005-2010

Exhibit ES-9:       Nuclear Medicine/Molecular Imaging Systems, Market Forecast, 2005-2010

Exhibit ES-10:   Diagnostic Ultrasound Systems, Market Forecast, 2005-2010

Exhibit ES-11:   Contrast-Enhanced Diagnostic Oncology Imaging, Procedure Volumes Forecast, 2005-2010

Exhibit ES-12:   Diagnostic Oncology-Related Contrast Agents and Radiopharmaceuticals,   Market Forecast, 2005-2010

Exhibit ES-13:   Oncology-Related Conventional X-Ray and Computed Tomography Imaging Contrast Agents, Market Forecast, 2005-2010

Exhibit ES-14:   Oncology-Related Magnetic Resonance Imaging Contrast Agents, Market Forecast, 2005-2010

Exhibit ES-15:   Oncology-Related Nuclear Medicine/Molecular Imaging Radiopharmaceuticals, Market Forecast, 2005-2010

Exhibit ES-16:   Standalone Computer-Aided Detection Systems for Oncology Applications, Market Forecast, 2005-2010

Exhibit ES-17:   Oncology-Related Less-Invasive Tissue Biopsy, Procedure Volumes Forecast, 2005-2010

Exhibit ES-18:   Oncology-Related Less-Invasive Tissue Biopsy Systems, Market Forecast, 2005-2010

Exhibit ES-19:   Automated and Vacuum-Assisted Breast Biopsy Devices, Market Forecast, 2005-2010

Exhibit ES-20:   Core Biopsy Needle Products, Market Forecast, 2005-2010

Exhibit ES-21:   Automated Papanicolaou Smear Preparation/Screening Systems, Market Forecast, 2005-2010

Exhibit ES-22:   Cancer Marker Testing Products, Market Forecast, 2005-2010

 

1. CANCER ETIOLOGY AND EPIDEMIOLOGY

1.1 Acquired Capabilities of Cancer Cells

1.2 Cataloging Genomic Alterations Involved in the Development of Cancer

1.3 Risk Factors Associated with the Development of Cancer

1.4 Cancer Staging

1.5 New Cancer Cases, Cancer Prevalence, and Deaths Due to Cancer

1.6 Clinical and Statistical Data for Selected Types of Cancer

1.6.1 Brain and Other Nervous System Cancers

1.6.1.1 Etiology

1.6.1.2 Epidemiology

1.6.2 Breast Cancer

1.6.2.1 Etiology

1.6.2.2 Epidemiology

1.6.3 Colorectal Cancer

1.6.3.1 Etiology

1.6.3.2 Epidemiology

1.6.4 Leukemia

1.6.4.1 Etiology

1.6.4.2 Epidemiology

1.6.5 Lung/Bronchus Cancer

1.6.5.1 Etiology

1.6.5.2 Epidemiology

1.6.6 Lymphoma

1.6.6.1 Etiology

1.6.6.2 Epidemiology

1.6.7 Melanoma

1.6.7.1 Etiology

1.6.7.2 Epidemiology

1.6.8 Oral Cavity and Pharyngeal Cancers

1.6.8.1 Etiology

1.6.8.2 Epidemiology

1.6.9 Ovarian Cancer

1.6.9.1 Etiology

1.6.9.2 Epidemiology

1.6.10 Pancreatic Cancer

1.6.10.1 Etiology

1.6.10.2 Epidemiology

1.6.11 Prostate Cancer

1.6.11.1 Etiology

1.6.11.2 Epidemiology

1.6.12 Urinary Bladder Cancer

1.6.12.1 Etiology

1.6.12.2 Epidemiology

1.6.13 Uterine Cancer

1.6.13.1 Etiology

1.6.13.2 Epidemiology

 

Exhibit 1-1:           Estimated New Cases, Prevalence, and Deaths for Selected Types of Cancer

Exhibit 1-2:           Brain and Other Nervous System Cancers, Facts And Figures

Exhibit 1-3:           Breast Cancer, Facts And Figures

Exhibit 1-4:           Colorectal Cancer, Facts And Figures

Exhibit 1-5:           Leukemia, Facts and Figures

Exhibit 1-6:           Lung/Bronchus Cancer, Facts And Figures

Exhibit 1-7:           Hodgkin Lymphoma, Facts and Figures

Exhibit 1-8:           Non-Hodgkin Lymphoma, Facts and Figures

Exhibit 1-9:           Melanoma, Facts and Figures

Exhibit 1-10:       Oral Cavity and Pharyngeal Cancers, Facts and Figures

Exhibit 1-11:       Ovarian Cancer, Facts and Figures

Exhibit 1-12:       Pancreatic Cancer, Fact and Figures

Exhibit 1-13:       Prostate Cancer, Facts And Figures

Exhibit 1-14:       Urinary Bladder Cancer, Fact and Figures

Exhibit 1-15:       Cancer of the Uterine Corpus, Facts and Figures

Exhibit 1-16:       Cancer of the Uterine Cervix, Facts and Figures

 

2. DIAGNOSTIC ONCOLOGY TECHNIQUES AND PROCEDURES

2.1 Diagnostic Imaging

2.1.1 Conventional X-Ray Imaging

2.1.1.1 Contrast Media

2.1.1.2 Computed Radiography and Digital Radiography

2.1.1.3 General Radiology/Fluoroscopy

2.1.1.4 Conventional X-Ray-Based Imaging, Oncology-Related Applications

2.1.1.5 Conventional X-Ray-Based Imaging, Procedure Volumes

2.1.2 Mammography

2.1.2.1 Digital Mammography

2.1.2.2 Computer-Aided Detection in Mammograph

2.1.2.3 Mammography, Procedure Volumes

2.1.3 Computed Tomography

2.1.3.1 Spiral Computed Tomography

2.1.3.2 Multislice Computed Tomography

2.1.3.3 Computed Tomography, Oncology-Related Applications

2.1.3.4 Computed Tomography, Procedure Volumes

2.1.4 Magnetic Resonance Imaging

2.1.4.1 Functional Magnetic Resonance Imaging

2.1.4.2 Proton Magnetic Resonance Spectroscopy

2.1.4.3 Interventional Magnetic Resonance

2.1.4.4 Contrast Media

2.1.4.5 Magnetic Resonance Imaging, Oncology-Related Applications

2.1.4.6 Magnetic Resonance Imaging, Procedure Volumes

2.1.5 Nuclear Medicine/Molecular Imaging

2.1.5.1 Gamma Camera Imaging

2.1.5.2 Positron Emission Tomography Scanner Imaging

2.1.5.3 Fusion Imaging Techniques

2.1.5.4 Radioimmunoscintigraphy

2.1.5.5 Nuclear Medicine/Molecular Imaging, Oncology-Related Applications

2.1.5.6 Nuclear Medicine/Molecular Imaging, Procedure Volumes

2.1.6 Diagnostic Ultrasound

2.1.6.1 Doppler Imaging

2.1.6.2 Duplex Ultrasonography

2.1.6.3 Contrast Media

2.1.6.4 Diagnostic Ultrasound, Oncology-Related Applications

2.1.6.5 Diagnostic Ultrasound, Procedure Volumes

2.1.7 Computer-Aided Detection

2.1.7.1 Computer-Aided Detection in Mammography-Based Breast Cancer Screening

2.1.7.2 Computer-Aided Detection in Early-Stage Lung Cancer Diagnostics

2.1.7.3 Computer-Aided Detection in Colorectal Cancer Diagnostics

2.1.8 Other Imaging Techniques

2.1.8.1 Electrical Impedance Scanning

2.1.8.2 Native Tissue Fluorescence/Opto-Electronic Spectroscopy

2.2 In Vitro Diagnostic Techniques

2.2.1 Tumor Tissue Biopsy

2.2.1.1 Tissue Biopsy Methods

2.2.1.1.1 Fine Needle Aspiration Biopsy

2.2.1.1.2 Core Needle Biopsy

2.2.1.1.3 Endoscopic Biopsy

2.2.1.1.4 Punch Biopsy

2.2.1.1.5 Surgical Biopsy

2.2.1.1.6 Tumor Tissue Biopsy, Procedure Volumes

2.2.2 Cancer Marker Testing

2.2.2.1 Tumor-Associated Markers

2.2.2.1.1 Alpha-Fetoprotein

2.2.2.1.2 Beta-Human Chorionic Gonadotropin

2.2.2.1.3 Bladder Tumor-Associated Antigen

2.2.2.1.4 Cancer Antigen 15-3

2.2.2.1.5 Cancer Antigen 19-9

2.2.2.1.6 Cancer Antigen 27-29

2.2.2.1.7 Cancer Antigen 125

2.2.2.1.8 Carcinoembryonic Antigen

2.2.2.1.9 Neuron-Specific Enolase

2.2.2.1.10 Prostate-Specific Antigen

2.2.2.1.11 Prostatic Acid Phosphatase

2.2.2.1.12 Selected Breast Cancer Markers

2.2.2.1.13 Selected Lung Cancer Markers

2.2.2.2 Genetic Cancer Markers

2.2.2.2.1 APC

2.2.2.2.2 ATM

2.2.2.2.3 BCL2

2.2.2.2.4 BIRC2 and BIRC4

2.2.2.2.5 BRCA1 and BRCA2

2.2.2.2.6 ERBB2

2.2.2.2.7 ER and PR

2.2.2.2.8 GADD45A

2.2.2.2.9 KLK2

2.2.2.2.10 PCNA

2.2.2.2.11 PMS2

2.2.2.2.12 RB1

2.2.2.2.13 SPP1

2.2.2.2.14 TP53

2.2.2.3 Developments in Site-Specific Cancer Markers

2.2.2.3.1 Bladder Cancer

2.2.2.3.2 Breast Cancer

2.2.2.3.3 Colorectal Cancer

2.2.2.3.4 Endometrial and Cervical Cancers

2.2.2.3.5 Esophageal Cancer

2.2.2.3.6 Hepatic Cancer

2.2.2.3.7 Lung Cancer

2.2.2.3.8 Ovarian Cancer

2.2.2.3.9 Pancreatic Cancer

2.2.2.3.10 Prostate Cancer

2.2.2.3.11 Telomerase-Based Universal Cancer Markers

2.2.2.4 Advanced Biomolecular Technologies for Cancer Detection   and Profiling

2.2.2.4.1 Immunohistochemical Analysis

2.2.2.4.2 Microarray Expression Analysis

2.2.2.4.3 Polymerase Chain Reaction Technology

2.2.2.4.4 Serial Analysis of Gene Expression

2.2.2.4.5 Surface-Enhanced Laser Desorption/Ionization

2.2.2.5 Cancer Chemosensitivity Testing

2.2.2.6 Cancer Marker Testing, Procedure Volumes

2.2.3 Cancer Screening

2.2.3.1 Fecal Occult Blood Testing

2.2.3.2 Helicobacter Pylori Testing

2.2.3.3 Human Papillomavirus Testing

2.2.3.4 Papanicolaou Smear Testing

2.2.3.5 Cancer Screening, Procedure Volumes

 

Exhibit 2-1:           Diagnostic Oncology, Procedure Volumes Forecast, 2005-2010

Exhibit 2-2:           United States, Selected Population Statistics, 2000, 2010, 2020, and 2030

Exhibit 2-3:           Conventional X-Ray-Based Imaging, Procedure Volumes Forecast, 2005-2010

Exhibit 2-4:           Mammography, Procedure Volumes Forecast, 2005-2010

Exhibit 2-5:           Computed Tomography, Procedure Volumes Forecast, 2005-2010

Exhibit 2-6:           Magnetic Resonance Imaging, Procedure Volumes Forecast, 2005-2010

Exhibit 2-7:           Nuclear Medicine/Molecular Imaging, Procedure Volumes Forecast, 2005-2010

Exhibit 2-8:           Diagnostic Ultrasound, Procedure Volumes Forecast, 2005-2010

Exhibit 2-9:           Tumor Tissue Biopsy, Procedure Volumes Forecast, 2005-2010

Exhibit 2-10:       2007, Selected Tumor Markers

Exhibit 2-11:       2007, Selected Genetic Cancer Markers

Exhibit 2-12:       Cancer Marker Testing, Procedure Volumes Forecast, 2005-2010

Exhibit 2-13:       Cancer Screening, Procedure Volumes Forecast, 2005-2010

 

3. DIAGNOSTIC ONCOLOGY PRODUCTS MARKET

3.1 Diagnostic Imaging Platforms

3.1.1 Conventional X-Ray-Based Imaging Systems

3.1.1.1 Products

3.1.1.2 Market Forecast

3.1.1.3 Competitive Analysis

3.1.2 Mammography Systems

3.1.2.1 Products

3.1.2.2 Market Forecast

3.1.2.3 Competitive Analysis

3.1.3 Computed Tomography Systems

3.1.3.1 Products

3.1.3.2 Market Forecast

3.1.3.3 Competitive Analysi

3.1.4 Magnetic Resonance Imaging Systems

3.1.4.1 Products

3.1.4.2 Market Forecast

3.1.4.3 Competitive Analysis

3.1.5 Nuclear Medicine/Molecular Imaging Systems

3.1.5.1 Products

3.1.5.2 Market Forecast

3.1.5.3 Competitive Analysis

3.1.6 Diagnostic Ultrasound Systems

3.1.6.1 Products

3.1.6.2 Market Forecast

3.1.6.3 Competitive Analysis

3.2 Imaging Contrast Agents and Radiopharmaceuticals

3.2.1 X-Ray Contrast Media

3.2.1.1 Products

3.2.1.2 Market Forecast

3.2.1.3 Competitive Analysis

3.2.2 Magnetic Resonance Imaging Contrast Media

3.2.2.1 Products

3.2.2.2 Market Forecast

3.2.2.3 Competitive Analysis

3.2.3 Nuclear Medicine/Molecular Imaging Radiopharmaceuticals

3.2.3.1 Products

3.2.3.2 Market Forecast

3.2.3.3 Competitive Analysis

3.3 Computer-Aided Detection Systems

3.3.1 Products

3.3.2 Market Forecast

3.3.3 Competitive Analysis

3.4 Less-Invasive Biopsy Products

3.4.1 Automated and Vacuum-Assisted Breast Biopsy Devices

3.4.1.1 Products

3.4.1.2 Market Forecast

3.4.1.3 Competitive Analysis

3.4.2 Core Biopsy Needles and Delivery Devices

3.4.2.1 Products

3.4.2.2 Market Forecast

3.4.2.3 Competitive Analysis

3.5 Automated Papanicolaou Smear Preparation/Screening Systems

3.5.1 Products

3.5.2 Market Forecast

3.5.3 Competitive Analysis

3.6 Cancer Marker Testing Systems

3.6.1 Products

3.6.2 Market Forecast

3.6.3 Competitive Analysis

 

Exhibit 3-1:           Oncology-Related Diagnostic Examinations, Procedure Volumes Forecast, 2005-2010

Exhibit 3-2:           Diagnostic Oncology Products, Market Forecast, 2005-2010

Exhibit 3-3:           Diagnostic Imaging, Procedure Volumes Forecast, 2005-2010

Exhibit 3-4:           Diagnostic Imaging Systems, Market Forecast, 2005-2010

Exhibit 3-5:           2007, Selected Conventional X-Ray-Based Imaging Systems

Exhibit 3-6:           Conventional X-Ray-Based Imaging Systems, Market Forecast, 2005-2010

Exhibit 3-7:           2006, Conventional X-Ray-Based Imaging Systems Market, Share by Supplier

Exhibit 3-8:           2007, Selected Mammography Systems

Exhibit 3-9:           Mammography Systems, Market Forecast, 2005-2010

Exhibit 3-10:       2006, Mammography Systems Market, Share by Supplier

Exhibit 3-11:       2007, Selected Computed Tomography Systems

Exhibit 3-12:       Computed Tomography Systems, Market Forecast, 2005-2010

Exhibit 3-13:       2006, Computed Tomography Systems Market, Share by Supplier

Exhibit 3-14:       2007, Selected Magnetic Resonance Imaging Systems

Exhibit 3-15:       Magnetic Resonance Imaging Systems, Market Forecast, 2005-2010

Exhibit 3-16:       2006, Magnetic Resonance Imaging Systems Market, Share by Supplier

Exhibit 3-17:       2007, Selected Nuclear Medicine/Molecular Imaging Systems

Exhibit 3-18:       Nuclear Medicine/Molecular Imaging Systems, Market Forecast, 2005-2010

Exhibit 3-19:       2006, Nuclear Medicine/Molecular Imaging Systems Market, Share by Supplier

Exhibit 3-20:       2007, Selected Diagnostic Ultrasound Systems

Exhibit 3-21:       Diagnostic Ultrasound Systems, Market Forecast, 2005-2010

Exhibit 3-22:       2006, Diagnostic Ultrasound Systems Market, Share by Supplier

Exhibit 3-23:       Contrast-Enhanced Diagnostic Oncology Imaging, Procedure Volumes Forecast, 2005-2010

Exhibit 3-24:       Diagnostic Oncology-Related Contrast Agents and Radiopharmaceuticals, Market Forecast, 2005-2010

Exhibit 3-25:       Oncology-Related Conventional X-Ray and Computed Tomography Imaging Contrast Agents, Market Forecast, 2005-2010

Exhibit 3-26:       2006, Oncology-Related Conventional X-Ray-Based Imaging and Computed Tomography Contrast Agents Market, Share by Supplier

Exhibit 3-27:       Oncology-Related Magnetic Resonance Imaging Contrast Agents, Market Forecast, 2005-2010

Exhibit 3-28:       2006, Oncology-Related Magnetic Resonance Imaging Contrast Agents Market, Share by Supplier

Exhibit 3-29:       Oncology-Related Nuclear Medicine/Molecular Imaging Radiopharmaceuticals, Market Forecast, 2005-2010

Exhibit 3-30:       2006, Gamma Camera-Based Nuclear Medicine/Molecular Imaging Radiopharmaceuticals Market, Share by Supplier

Exhibit 3-31:       2006, Positron Emission Tomography-Based Nuclear Medicine/Molecular Imaging Radiopharmaceuticals Market, Share by Supplier

Exhibit 3-32:       2007, Selected Computer-Aided Detection Systems

Exhibit 3-33:       Standalone Computer-Aided Detection Systems for Oncology Applications, Market Forecast, 2005-2010

Exhibit 3-34:       2006, Standalone Computer-Aided Detection Systems Market, Share by Supplier

Exhibit 3-35:       Oncology-Related Less-Invasive Tissue Biopsy, Procedure Volumes Forecast, 2005-2010

Exhibit 3-36:       Oncology-Related Less-Invasive Tissue Biopsy Systems, Market Forecast, 2005-2010

Exhibit 3-37:       2007, Selected Automated and Vacuum-Assisted Breast Biopsy Devices

Exhibit 3-38:       Automated and Vacuum-Assisted Breast Biopsy Devices, Market Forecast, 2005-2010

Exhibit 3-39:       2006, Automated and Vacuum-Assisted Breast Biopsy Devices Market, Share by Supplier

Exhibit 3-40:       Core Biopsy Needle Products, Market Forecast, 2005-2010

Exhibit 3-41:       2006, Core Biopsy Needles and Delivery Devices Market, Share by Supplier

Exhibit 3-42:       2007, Selected Automated Papanicolaou Smear Preparation/Screening Systems

Exhibit 3-43:       Automated Papanicolaou Smear Preparation/Screening Systems, Market Forecast, 2005-2010

Exhibit 3-44:       2006, Automated Papanicolaou Smear Preparation/Screening Systems Market, Share by Supplier

Exhibit 3-45:       Cancer Marker Testing Products, Market Forecast, 2005-2010

Exhibit 3-46:       2006, Cancer Marker Testing Products Market, Share by Supplier

 

4. COMPANY PROFILES

4.1             Abbott Diagnostics/Abbott Laboratories

4.2             C. R. Bard, Inc.

4.3             Bayer HealthCare Pharmaceuticals, Inc./Bayer HealthCare LLC/ Bayer AG

4.4             Bracco Diagnostics, Inc./Bracco Group

4.5             Bristol-Myers Squibb Company

4.6             Cardinal Health, Inc.

4.7             Cytyc Corporation

4.8             Digene Corporation/QIAGEN NV

4.9             Ethicon Endo-Surgery, Inc./Johnson & Johnson

4.10         GE Healthcare/General Electric Company

4.11         Hologic, Inc.

4.12         iCAD, Inc.

4.13         Mallinckrodt, Inc./Covidien LTD

4.14         Philips Medical Systems, Inc./Royal Philips Electronics NV

4.15         Siemens Medical Solutions/Siemens AG

 

APPENDIX:   COMPANY LISTING



COMPANIES COVERED:

  1. Abbott Diagnostics/Abbott Laboratories
  2. C. R. Bard, Inc.
  3. Bayer HealthCare Pharmaceuticals, Inc./Bayer HealthCare LLC/ Bayer AG
  4. Bracco Diagnostics, Inc./Bracco Group
  5. Bristol-Myers Squibb Company
  6. Cardinal Health, Inc.
  7. Cytyc Corporation
  8. Digene Corporationv/QIAGEN NV
  9. Ethicon Endo-Surgery, Inc./Johnson & Johnson
  10. GE Healthcare/General Electric Company
  11. Hologic, Inc.
  12. iCAD, Inc.
  13. Mallinckrodt, Inc./Covidien LTD
  14. Philips Medical Systems, Inc./Royal Philips Electronics NV
  15. Siemens Medical Solutions/Siemens AG
Contact Us

Need help finding medtech research? Let us help you!